['colorectal adenocarcinoma']
['regorafenib 160 mg']

        Inclusion Criteria:

          -  Metastatic colorectal cancer with histological proof

          -  Measurable disease according RECIST 1.1

          -  Age ≥ 70 years

          -  ECOG ≤ 1

          -  Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3,
             bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N,
             TP≥ 70%, Creatinine clairance ≥ 30 mL/min

          -  Patient without response to 5FU chemotherapy or anti-vegf treatment or anti EGFR
             treatment (if RAS wild-type), in progression during this treatment or treatment
             stopped because of toxicities

          -  Geriatric Questionnaires answered

          -  Life-expectancy ≥ 3 months

          -  Informed Consent Signed

        Exclusion Criteria:

          -  Not able to swallow tablets (crushed tablets are not allowed)

          -  Previous treatment with regorafenib or other multikinase treatment

          -  Other cancer during the last 5 years, excepted in-situ cervix cancer, skin cancer non
             melanoma and cancer of the bladder curatively treated

          -  Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the
             last 2 weeks previous inclusion

          -  Toxicity > grade 1 not resolved with previous treatment

          -  Major surgery in the 28 days before the inclusion

          -  Non cicatrized injury, ulcer or bone fracture

          -  Congestive Cardiac insufficiency classe >2 (NYHA)

          -  Unstable angor in the last 3 months

          -  Myocardial Infraction in the 6 months before inclusion

          -  HTA not controlled

          -  Pheochromocytome

          -  Arterial or venous thromboembolism in the past 6 months

          -  Infection of grade > 2

          -  VIH infection

          -  B or C hepatitis necessiting a specific treatment

          -  Cirrhosis

          -  Suspicion of brain metastasis or brain metastasis

          -  Haemorraghe ofgrade >3 in the last weeks

          -  Symptomatic Pulmonary fibrosis

          -  Proteinuria > grade 3

          -  Malabsorption

          -  Allergy know to the treatment or to one similar treatment or to one treatment
             component

          -  Systemic anti-cancer drug during the study or the the last 4 weeks

          -  Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor

          -  Social, psychological or medical condition which can interfere with the study
             participation
      